Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 51c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $3.67, $0.51 better than the analyst estimate of $3.16. Revenue for the quarter came in at $508.2 million versus the consensus estimate of $465.95 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2019 EPS of $14.30-$15.00, versus the consensus of $14.60. Jazz Pharmaceuticals sees FY2019 revenue of $2.05-2.13 billion, versus the consensus of $2.07 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance
• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance